Cargando…

PB1814: RARE PHENOTYPE WITH CD33 ABSENT IN ACUTE MYELOID LEUKEMIA MIMICKING MRD POSITIVITY: A CASE REPORT

Detalles Bibliográficos
Autores principales:	O Marani, L., Costa, A., B Silva, F., A Madeira, M. I., S Scheucher, P., L S Schiavinato, J., G Lima, A. S., B B Pagnano, K., K Duarte, B., Freeman, S., M Rego, E., Traina, F., L Figueiredo-Pontes, L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430762/ http://dx.doi.org/10.1097/01.HS9.0000850108.96421.f0

Ejemplares similares

PB1980: MULTIPLE MYELOMA: ADOPTING MRD BY NEXT GENERATION FLOW CYTOMETRY (NGF) AND FUNCTIONAL IMAGING GUIDED CONSOLIDATION INTO CLINICAL ROUTINE
por: Boeckle, D., et al.
Publicado: (2022)

PB1814: THERAPEUTIC POTENTIAL AND STRATEGIES OF PIM447, A PAN-PIM INHIBITOR, TARGETING REFRACTORY MYELOID LEUKEMIA WITH KIT-DRIVEN T(8/21)
por: Tseng, Chi-Yang, et al.
Publicado: (2023)

PB1781: THE APPLICATION OF CF-DNA FOR NGS MRD STUDIES IN PATIENTS WITH LMA IMPROVES THE SENSITIVITY OF THE METHOD WITH RESPECT TO CTC.
por: Sánchez-Redondo, Noemí Álvarez, et al.
Publicado: (2023)

PB2149: MINIMAL RESIDUAL DISEASE (MRD) DETECTION TRENDING AS A PRIMARY ENDPOINT IN CERBA RESEARCH MULTIPLE MYELOMA (MM) TRIALS
por: Gaspo, Rania, et al.
Publicado: (2023)

PB2376: ASSAY DEVELOPMENT AND VALIDATION OF IG-HTS TO MONITOR MRD IN PLASMA OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
por: Wu, Jinghua, et al.
Publicado: (2023)

PB1806: ULTRA-SENSITIVE MINIMAL RESIDUAL DISEASE (MRD) MONITORING FOR LEUKEMIA PATIENTS USING SUPERRCA MUTATION ASSAYS WITH FLOW CYTOMETER READOUT
por: Chen, Lei, et al.
Publicado: (2023)

P889: WILL OUTCOME IMPROVE BY TREATING MULTIPLE MYELOMA PATIENTS AT MRD RELAPSE? THE REMNANT STUDY (RELAPSE FROM MRD NEGATIVITY AS INDICATION FOR TREATMENT)
por: Askeland, F. B., et al.
Publicado: (2022)

PB1771: THE SIGNIFICANCE OF MRD DETECTION BY FLOW CYTOMETRY IN TRACING R/R B-ALL PATIENTS RECEIVING CD-19-CART BRIDGING TO ALLO-HSCT
por: chen, M., et al.
Publicado: (2022)

PB2443: APPLICABILITY OF SHORT TANDEM REPEAT (STR) IN LEUKEMIA PATIENTS RECEIVED ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THE ERA OF MINIMAL RESIDUAL DISEASE (MRD)
por: Kim, Juhyung, et al.
Publicado: (2023)

PB1762: A NEW MONOCLONAL ANTIBODY PROVIDES INSIGHTS ON NPM1 MUTANT SUBCELLULAR EXPRESSION, INTRACLONAL CELL DIFFERENTIATION AND MRD IN NPM1-MUTATED AML
por: Falini, Brunangelo, et al.
Publicado: (2023)

PB1866: IS ALLO-HSCT IN CR1 NECESSARY FOR AML PATIENTS WITH MRD NEGATIVITY ACHIEVED AFTER THE FIRST INDUCTION COURSE? RUSSIAN PROSPECTIVE MULTICENTER RANDOMIZED TRIAL IN AML PATIENTS UNDER THE AGE OF 60
por: Parovichnikova, Elena, et al.
Publicado: (2023)

The French Revolution, 1770-1814 /
por: Furet, François, 1927-1997
Publicado: (1996)

Freedom and organisation, 1814-1914
por: Russell, Bertrand, 1872-1970
Publicado: (1934)

PB1963: A RARE CASE OF MULTIPLE SOLITARY PLASMOCYTOMA
por: Mlayah, Z., et al.
Publicado: (2022)

PB2276: EARLY ADMINISTRATION OF REMDESIVIR PLUS CONVALESCENT PLASMA THERAPY IS EFFECTIVE TO TREAT COVID-19 PNEUMONIA IN B-CELL DEPLETED PATIENTS WITH HEMATOLOGICAL MALIGNANCIES
por: Pinczes, L. I., et al.
Publicado: (2022)

PB2340: INFLUENCE OF INITIAL CLINICAL FEATURES IN THERAPEUTIC DECISIONS AND DIAGNOSTIC PROCESS OF ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA. A REAL WORLD EXPERIENCE
por: Bolea, L., et al.
Publicado: (2022)

Ludwik Maurycy Hirschfeld (1814–1876)
por: Gonkowski, Ignacy, et al.
Publicado: (2020)

PB1835: THE ISTH-DIC SCORE PREDICTS 30-DAYS OUTCOME IN NON-M3 ACUTE MYELOID LEUKEMIA PATIENTS
por: Paterno, G., et al.
Publicado: (2022)

PB1775: DEVELOPMENT OF ASSAY CALIBRATION MEHTHODOLOGY FOR CEPHEID XPERT® NPM1 MUTATION PROTOTYPE ASSAY
por: Liu, Y., et al.
Publicado: (2022)

Chromosomal characteristics and distribution of rDNA sequences in the brook trout Salvelinus fontinalis (Mitchill, 1814)
por: Śliwińska-Jewsiewicka, A., et al.
Publicado: (2015)

PB2269: HUMORAL AND T-CELL RESPONSES TO SARS-COV2 VACCINATION IN PATIENTS WITH MULTIPLE MYELOMA MANAGED IN THE COMMUNITY SETTING
por: Holik, H., et al.
Publicado: (2022)

PB2082: POPULATION-WIDE PATTERNS OF CARE IN MANTLE CELL LYMPHOMA IN AUSTRALIA: AN ANALYSIS OF THE PHARMACEUTICAL BENEFITS SCHEME DATASET
por: Tam, C., et al.
Publicado: (2022)

PB2167: NGS CLONALITY TESTING FOR A DIFFERENTIAL DIAGNOSIS OF MYCOSIS FUNGOIDES
por: Sidorova, Y., et al.
Publicado: (2022)

PB1830: HIGH EARLY MORTALITY RATES IN OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH INTENSIVE CHEMOTHERAPY IN TWO ACADEMIC CENTERS IN BRAZIL
por: Lisboa Nogueira, F., et al.
Publicado: (2022)

PB1875: TREATMENT OF YOUNGER PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN TUNISIA: FCR STILL STANDARD FOR FIRST-LINE THERAPY
por: Miled, W., et al.
Publicado: (2022)

PB1955: THE AGENDA FOR FUTURE MULTIPLE MYELOMA RESEARCH ACCORDING TO PATIENTS, CAREGIVERS, AND CLINICIANS
por: Fowler, S., et al.
Publicado: (2022)

PB2115: TRIAL IN PROGRESS: A RANDOMIZED PHASE II STUDY OF MB-CART2019.1 COMPARED TO STANDARD OF CARE THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY DLBCL INELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION
por: Borchmann, P., et al.
Publicado: (2022)

PB1851: EARLY DEATHS IN PATIENTS WITH NEWLY DIAGNOSED ACUTE PROMYELOCYTIC LEUKEMIA: A SINGLE-CENTER RETROSPECTIVE STUDY FROM A GENERAL HOSPITAL
por: Yohannan, B., et al.
Publicado: (2022)

PB2268: IMPACT OF HEMATOLOGICAL DISORDERS ON MORTALITY AND SERIOUS OUTCOMES IN SARS-COV-2 INFECTION: A MULTICENTER COHORT STUDY
por: Hernandez Perez, A. P., et al.
Publicado: (2022)

PB1945: CLINICAL AND MOLECULAR CHARACTERISTICS OF CHILDREN WITH DIAMOND-BLACKFAN ANEMIA (DBA): A SINGLE CENTER EXPERIENCE IN ARGENTINA
por: Mininni, M. F., et al.
Publicado: (2022)

Legislación y estadísticas electorales. 1814-1997
Publicado: (1997)

The Medico-Chirurgical Society of Glasgow, 1814-1907
por: Downie, Walker
Publicado: (1907)

PB1949: ELTROMBOPAG IN CHINESE PATIENTS WITH REFRACTORY OR RELAPSED SEVERE APLASTIC ANEMIA: A NON-RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE II STUDY ASSESSING THE SAFETY AND EFFICACY OF ELTROMBOPAG
por: Chang, H., et al.
Publicado: (2022)

Absent Anterior Cruciate Ligament
por: Vanden Bossche, S., et al.
Publicado: (2015)

PB1935: MANAGEMENT OF NON-SEVERE APLASTIC ANEMIA: LABORATORY WORKUP AND TREATMENT PATTERNS.
por: Cassanello, G., et al.
Publicado: (2022)

PB2136: PLANNED-USE GLUCARPIDASE FOR OUTPATIENT HIGH DOSE METHOTREXATE (HD-MTX) ADMINISTRATION IN PATIENTS WITH CNS LYMPHOMA (CNSL) DURING THE COVID-19 PANDEMIC
por: Schaff, L., et al.
Publicado: (2022)

PB2216: VACUOLES APPEAR IN RED BLOOD CELLS TRANSFUSED TO PATIENTS WITH SICKLE CELL DISEASE-RELATED HYPOSPLENISM
por: Dumas, L., et al.
Publicado: (2022)

PB1844: THROMBOTIC EVENTS DURING REMISSION INDUCTION OF ACUTE MYELOID LEUKEMIA – FREQUENCY AND RELATED FACTORS
por: Silva, W., et al.
Publicado: (2022)

Sablefish (Anoplopoma fimbra Pallas, 1814) plasma biochemistry and hematology reference intervals including blood cell morphology
por: Schubiger, Carla B., et al.
Publicado: (2021)

Thomas Burn Catherwood and the medical department of Wellington's army: 1809-1814.
por: Crowe, K
Publicado: (1976)

Cannot write session to /tmp/vufind_sessions/sess_jj62j2hkens6346vsklu8pc235